Company Analysis

Bionano Genomics, Inc. (BNGO)

Nasdaq: BNGO · Laboratory Analytical Instruments · San Diego, CA · filing with the SEC since 2007
Grade3.3
◀ Past 2.2● Present 3.4▶ Future 4.1
1 est.

Who runs Bionano Genomics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Luderer Albert
Interim Chief Executive. First filing Aug 2018, latest Sep 9, 2026, 2 filings in all.
Officers reporting now
7
of 12 people with a filing in the last fifteen months
Directors reporting now
5
26 people on the record since 2018
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Luderer AlbertInterim Chief ExecutiveAug 2018Sep 9, 2026none
Borodkin MarkChief Operating OfficerAug 2018Aug 5, 2026none
Hastie Alex ReidChief Scientific OfficerJul 2026Aug 5, 2026none
Adamchak MarkPrincipal Accounting OfficerSep 2024Aug 5, 2026none
Dixon Jonathan V.General CounselMar 2023Aug 5, 2026none
Chaubey AlkaCHIEF MEDICAL OFFICERSep 2020Jun 3, 2026none
Holmlin R. ErikPRESIDENT AND CEOAug 2018Feb 18, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Barker David LdirectorAug 2018May 14, 2026none
Linney YvonnedirectorMay 2020May 14, 2026none
Rajkovic AleksandardirectorFeb 2022May 14, 2026none
Twomey Christopher JdirectorAug 2018May 14, 2026none
Vuori Kristiina MddirectorJun 2019May 14, 2026none
Earlier names on the record28, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton BNGO · research, not advice